Jennifer Doudna’s New Gene Editing Company Launches With A $20 Million Round To Develop Genetic Medicines What if you had a tool to change the genetic instructions that cause disease?
That's what San Francisco-based Scribe Therapeutics hopes to do with its next-generation platform for gene editing.